The FDA's approval of the opoid painkiller Zohydro last week came without a requirement that the drug have biochemical mechanisms to control abuse, setting it apart from other drugs, such as OxyContin and Opana, that have abuse-deterrent formulations. Zogenix, the pharmaceutical company that developed Zohydro, said it plans to offer an abuse-deterrent form of the drug and an FDA representative said the agency makes decisions on abuse-deterrent requirements on a case-by-case basis.

Related Summaries